Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258757 | 1.00 | CTSL (0.45) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL1257540 | 0.82 | CTRB1 (0.40) | — | |
| SCHEMBL1257536 | 0.82 | CTRB1 (0.40) | — | |
| SCHEMBL21315755 | 0.82 | ALDH1A1 (0.43) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL21488785 | 0.79 | ALDH1A1 (0.49) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL21488788 | 0.79 | ALDH1A1 (0.49) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL10250520 | 0.76 | CTSL (0.68) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL764062 | 0.76 | CTSL (0.68) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL6387189 | 0.76 | CTSL (0.68) | CTSLCTSSCTSBCTSKALDH1A1 | |
| SCHEMBL21488724 | 0.74 | ALDH1A1 (0.45) | CTSLCTSSCTSBCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252940-B2 | 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection | UNIVERSITY OF WASHINGTON (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110039849-A1 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | UNIVERSITY OF WASHINGTON (US) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039849-A1 | 5-SUBSTITUTED-2-IMINO-THIAZOLIDINONE COMPOUNDS AND THEIR USE AS INHIBITORS OF BACTERIAL INFECTION | IRF3, GDI2, TLR5 | CTSL 867/4885CTSS 1511/4885CTSB 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.